MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics 
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery...
Alignment Healthcare to Introduce Award-Winning Medicare Advantage Plans with its Unique Care Model to Half a Million Medicare-Eligible Adults in Florida
ORANGE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, will begin offering Alignment...
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY...
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
LG Chem to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its T-cell therapy candidates...
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III
ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022ProKidney receives...
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc.,...
Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022
PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that...
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022
WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu
Partnership aims to expand the Transfusion Transmissible Infections, other Infectious Diseases, and clinical diagnostics assay menu on Quotient’s multimodality, multiplexed...
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN...
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022...
Aurora Spine Announces New FDA indication clearance of Lumbar Spinal Stenosis for its ZIP™ series of MIS implants
CARLSBAD, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™
-- Training for physical therapists treating patients with multiple sclerosis (MS) is now available on demand --NEWTOWN, Pa., July 12,...
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to manufacture cGMP...
Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Verapamil PM and Verelan SR Products
Societal to Receive Greater Portion of Profit Sharing from Verapamil PM Product Sales Societal Awarded Potential New GMP Manufacturing Agreements...
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity
--All evaluable patients (N=11) achieved BMI decrease of more than 5 percent at 16 weeks on setmelanotide therapy-- --17.2 percent...
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a...
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation...
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical
As Part of the Settlement, Catalyst has Acquired Certain of Jacobus’ Intellectual Property Rights, Including the U.S. and Mexico Rights...